Gilead’s CAR-T dominates Nov MSAC

By Megan Brodie 2 years ago | In MedTech, Products
  • 2 years ago

29 July 2022 Gilead’s second CAr-T to be approved in Australia, TECARTUS (brexucabtagene autoleucel), has…

This is subscriber-only content. Please login to continue reading.